Our CEO Neil Miller presenting today at #GenesisLondon2023 as a finalist for the #BioNewsRoundAward. Fingers crossed 🤞 #mitochondria #mPTP #Parkinson’s #MND

Looking forward to being in San Francisco at #JPM24 week to share progress of our first-in-class brain-penetrant, oral small molecule inhibitors of #mPTP as potential disease modifying treatments for #NeurodegenerativeDisorders #Parkinsons #ALS #MND #DrugDiscovery #mitrochondria

Today is #WorldLewyBodyDay. Lewy bodies are closely linked to Parkinson's, and some forms of dementia. We're funding a study to tackle hallucinations associated with Parkinson's and Lewy Body Dementia. Find out more about the TOP HAT trial 👉🏼 prksn.uk/3u4Lcbo

#WorldParkinsonsDay. We are applying #innovative #science to develop inhibitors of the mitochondrial permeability transition pore (#mPTP) with the aim of restoring mitochondrial function and slowing or halting the progression of #Parkinsons #ALS #MND #NeurodegenerativeDisorders

Wednesday next week! Join this webinar with Gilles Ouvry of NRGTherapeutics to find out how the Cambridge Structural Database (CSD) can be used to inspire #drugdesign. 📅Wed, 24th April at 3 p.m. (BST) Register: ccdc-info.com/3PNIYF4 #Cheminformaticians #DrugDiscovery

Our CEO will be at obn #BioTrinity 2024, April 23-24. Come along to his panel on Neurodegenerative & Age-Related Diseases R&D, or get in touch to discuss our brain-penetrant, oral small molecule #mPTP inhibitors as disease modifying therapies for #Parkinson’s, #ALS #MND

X/Twitter Our CEO, CSO and COO will all at @BIO International Convention 3-6 June in San Diego. Get in touch to meet up to discuss our brain-penetrant, oral small molecule #mPTP inhibitors as disease modifying therapies for #Parkinson’s, #ALS #MND #NeurodegenerativeDiseases

We have been awarded a grant from Target ALS in collaboration with #Biospective for PoC studies of our mPTP inhibitor for #ALS/#MND. The project will generate high-quality data from a modified ALS TDP-43 mouse model, accelerating progress from preclinical to clinical studies

Tomorrow is #WorldAlzheimersDay We celebrate advances in #biology & #drugdiscovery that are delivering new treatments for #Alzheimers. At NRG we are applying #innovative #science to develop inhibitors of the mitochondrial permeability transition pore for #ALS #MND #Parkinsons.

See article on mitochondrial therapeutics including quotes from our CEO and overview of out #mPTP targeting therapeutics for #neurologicaldisorders #AML ~MND #Parkinsons

Our CEO will all at #BioEurope 4-7 November in Stockholm. Get in touch to meet up to discuss our brain-penetrant, oral small molecule #mPTP inhibitors as disease modifying therapies for #Parkinson’s #ALS #MND #NeurodegenerativeDiseases #DrugDevelopment #Biotech #Networking

Delighted to announce that we have selected our first development candidate, NRG5051, and secured a $5M grant from michaeljfox.org (#MJFF) for the development of mitochondrial permeability transition pore (mPTP) inhibitors to treat #Parkinson’s and #ALS. tinyurl.com/yp9x4vaw

We greatly appreciate the support of michaeljfox.org (#MJFF) which has awarded us a $5M Therapeutics Pipeline Program grant for the development of mitochondrial permeability transition pore (mPTP) Inhibitors to treat neurodegenerative diseases. tinyurl.com/5f8prm88

We are actively investing in 12 research projects through the Parkinson’s Virtual Biotech. Researchers are exploring every angle including work to test if an inflammation busting molecule could stop the early causes of Parkinson's. Watch the video to find out more 👇🏽

Thanks to Mark Mardell Alan Cameron & NRGTherapeutics for leading the conversation at Parkinson's UK annual lecture. A common theme - we all need to make more noise and get #Parkinsons noticed and in more conversations. Join the discussion here 👇🏻 parkinsons.org.uk/research/get-i…

Dear Wes Streeting, Tofersen is life-saving, and free, yet around 20 people with SOD1 MND are being denied access to it. They do not have time to wait. You’ve got the power. Please use it. #PrescribeLife

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Stevenage, UK based NRGTherapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS. Full video: biotechtv.com/post/nrg-thera…

“It has the potential to stop or slow Parkinson’s.” NRG Therapeutics has secured an impressive £50 million to advance their drug, NRG5051, into clinical trials for people with Parkinson’s. Dr Lynsey Bilsland is here to tell you more.

🔬NRGTherapeutics has raised £50 million in Series B funding. techfundingnews.com/nrg-therapeuti… The round was led by SV Health Investors’ Dementia Discovery Fund and joined by British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds and brandon capital.

NRG Therapeutics NRGTherapeutics announce oversubscribed £50m ($67m) series B financing to deliver clinical data in #Parkinsons & proof of concept in #ALS/MND; This is part of the Parkinson's UK Virtual Biotech programme nrgtherapeutics.com/news/19/51/NRG…